Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway
Am J Transl Res. 2024 Mar 15;16(3):1036. doi: 10.62347/SBSI1515. eCollection 2024.ABSTRACT[This corrects the article on p. 2656 in vol. 15, PMID: 37193155.].PMID:38586108 | PMC:PMC10994810 | DOI:10.62347/SBSI1515 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Zhengchang He Shaoxian Shen Yuyao Yi Lingli Ren Huan Tao Fujue Wang Yongqian Jia Source Type: research
Exploring the molecular mechanisms between lymphoma and myelofibrosis
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.ABSTRACTLymphoma is a heterogeneous malignant tumor with an increasing annual incidence. As the lymphoma progresses, bone marrow (BM) invasion gradually appears. Myelofibrosis (MF) can accompany a variety of hematological malignancies, including lymphoma, and multiple myeloma. The prognosis of lymphoma patients with myelofibrosis is poor, and a fundamental reason is that there are few studies on the correlation and pathogenesis of the two diseases. In this review, we examine the potential pathogenesis and the correlation of the two disease...
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Jun-Nuan Wang Yan Li Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Exploring the molecular mechanisms between lymphoma and myelofibrosis
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.ABSTRACTLymphoma is a heterogeneous malignant tumor with an increasing annual incidence. As the lymphoma progresses, bone marrow (BM) invasion gradually appears. Myelofibrosis (MF) can accompany a variety of hematological malignancies, including lymphoma, and multiple myeloma. The prognosis of lymphoma patients with myelofibrosis is poor, and a fundamental reason is that there are few studies on the correlation and pathogenesis of the two diseases. In this review, we examine the potential pathogenesis and the correlation of the two disease...
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Jun-Nuan Wang Yan Li Source Type: research
Erratum: CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway
Am J Transl Res. 2024 Mar 15;16(3):1036. doi: 10.62347/SBSI1515. eCollection 2024.ABSTRACT[This corrects the article on p. 2656 in vol. 15, PMID: 37193155.].PMID:38586108 | PMC:PMC10994810 | DOI:10.62347/SBSI1515 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Zhengchang He Shaoxian Shen Yuyao Yi Lingli Ren Huan Tao Fujue Wang Yongqian Jia Source Type: research
